Stat5 exerts distinct, vital functions in the cytoplasm and nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL leukemia cells

Cancers

Volumn 7, Issue 1, 2015, Pages 503-537

  Weber, Axel ^a   Borghouts, Corina ^b   Brendel, Christian ^c   Moriggl, Richard ^d   Delis, Natalia ^a   Brill, Boris ^a   Vafaizadeh, Vida ^a   Groner, Bernd ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b Ganymed Pharmaceuticals AG   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bcr Abl; Canonical non canonical; Chronic myeloid leukemia (CML); Human erythroid leukemia (HEL); Jak2(V617F); Peptide aptamer (PA); Protein lentiviral transduction; RNA interference (RNAi); Signal transducer and activator of transcription 5 (Stat5)

Indexed keywords

APTAMER; BCR ABL PROTEIN; JANUS KINASE 2; SHORT HAIRPIN RNA; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CANCER GROWTH; CELL DEATH; CELL NUCLEUS; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING DOMAIN; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; K562 CELL LINE; LEUKEMIA CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSACTIVATION;

EID: 84982678174     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7010503     Document Type: Article

References (102)

1. Groner, B.; Hennighausen, L. The versatile regulation of cellular events by jak-stat signaling: From transcriptional control to microtubule dynamics and energy metabolism. Horm. Mol. Biol. Clin. Investg. 2012, 10, 193-200.
2. Groner, B.; Vafaizadeh, V. Cytokine regulation of mammary gland development and epithelial cell functions through discrete activities of stat proteins. Mol. Cell. Endocrinol. 2014, 382, 552-559.
3. Walker, S.R.; Xiang, M.; Frank, D.A. Distinct roles of stat3 and stat5 in the pathogenesis and targeted therapy of breast cancer. Mol. Cell. Endocrinol. 2014, 382, 616-621.
4. Kim, D.J.; Chan, K.S.; Sano, S.; Digiovanni, J. Signal transducer and activator of transcription 3 (stat3) in epithelial carcinogenesis. Mol. Carcinog. 2007, 46, 725-731.
5. Vafaizadeh, V.; Klemmt, P.; Brendel, C.; Weber, K.; Doebele, C.; Britt, K.; Grez, M.; Fehse, B.; Desrivieres, S.; Groner, B. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 2010, 28, 928-938.
6. Groner, B. Determinants of the extent and duration of stat3 signaling. JAKSTAT 2012, 1, 211-215.
7. Mertens, C.; Darnell, J.E., Jr. Snapshot: Jak-stat signaling. Cell 2007, 131, 612.
8. Wakao, H.; Schmitt-Ney, M.; Groner, B. Mammary gland-specific nuclear factor is present in lactating rodent and bovine mammary tissue and composed of a single polypeptide of 89 kda. J. Biol. Chem. 1992, 267, 16365-16370.
9. Wakao, H.; Gouilleux, F.; Groner, B. Mammary gland factor (mgf) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1994, 13, 2182-2191.
10. Liu, X.; Robinson, G.W.; Gouilleux, F.; Groner, B.; Hennighausen, L. Cloning and expression of stat5 and an additional homologue (stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. USA 1995, 92, 8831-8835.
11. Hennighausen, L.; Robinson, G.W. Interpretation of cytokine signaling through the transcription factors stat5a and stat5b. Genes Dev. 2008, 22, 711-721.
12. Horvath, C.M. Stat proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci. 2000, 25, 496-502.
13. Herrington, J.; Rui, L.; Luo, G.; Yu-Lee, L.Y.; Carter-Su, C. A functional DNA binding domain is required for growth hormone-induced nuclear accumulation of stat5b. J. Biol. Chem. 1999, 274, 5138-5145.
14. Reich, N.C.; Liu, L. Tracking stat nuclear traffic. Nat. Rev. Immunol. 2006, 6, 602-612.
15. Heltemes-Harris, L.M.; Farrar, M.A. The role of stat5 in lymphocyte development and transformation. Curr. Opin. Immunol. 2012, 24, 146-152.
16. Kornfeld, J.W.; Grebien, F.; Kerenyi, M.A.; Friedbichler, K.; Kovacic, B.; Zankl, B.; Hoelbl, A.; Nivarti, H.; Beug, H.; Sexl, V.; et al. The different functions of stat5 and chromatin alteration through stat5 proteins. Front. Biosci. 2008, 13, 6237-6254.
17. Mandal, M.; Powers, S.E.; Maienschein-Cline, M.; Bartom, E.T.; Hamel, K.M.; Kee, B.L.; Dinner, A.R.; Clark, M.R. Epigenetic repression of the igk locus by stat5-mediated recruitment of the histone methyltransferase ezh2. Nat. Immunol. 2011, 12, 1212-1220.
18. Cui, Y.; Hosui, A.; Sun, R.; Shen, K.; Gavrilova, O.; Chen, W.; Cam, M.C.; Gao, B.; Robinson, G.W.; Hennighausen, L. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 2007, 46, 504-513.
19. Engblom, D.; Kornfeld, J.W.; Schwake, L.; Tronche, F.; Reimann, A.; Beug, H.; Hennighausen, L.; Moriggl, R.; Schutz, G. Direct glucocorticoid receptor-stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev. 2007, 21, 1157-1162.
20. Nevalainen, M.T.; Ahonen, T.J.; Yamashita, H.; Chandrashekar, V.; Bartke, A.; Grimley, P.M.; Robinson, G.W.; Hennighausen, L.; Rui, H. Epithelial defect in prostates of stat5a-null mice. Lab. Investig. 2000, 80, 993-1006.
21. Yamaji, D.; Na, R.; Feuermann, Y.; Pechhold, S.; Chen, W.; Robinson, G.W.; Hennighausen, L. Development of mammary luminal progenitor cells is controlled by the transcription factor stat5a. Genes Dev. 2009, 23, 2382-2387.
22. Wang, Z.; Li, G.; Tse, W.; Bunting, K.D. Conditional deletion of stat5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 2009, 113, 4856-4865.
23. Wierenga, A.T.; Vellenga, E.; Schuringa, J.J. Maximal stat5-induced proliferation and self-renewal at intermediate stat5 activity levels. Mol. Cell. Biol. 2008, 28, 6668-6680.
24. Yao, Z.; Cui, Y.; Watford, W.T.; Bream, J.H.; Yamaoka, K.; Hissong, B.D.; Li, D.; Durum, S.K.; Jiang, Q.; Bhandoola, A.; et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc. Natl. Acad. Sci. USA 2006, 103, 1000-1005.
25. Sitrin, J.; Ring, A.; Garcia, K.C.; Benoist, C.; Mathis, D. Regulatory t cells control nk cells in an insulitic lesion by depriving them of il-2. J. Exp. Med. 2013, 210, 1153-1165.
26. Grebien, F.; Kerenyi, M.A.; Kovacic, B.; Kolbe, T.; Becker, V.; Dolznig, H.; Pfeffer, K.; Klingmuller, U.; Muller, M.; Beug, H.; et al. Stat5 activation enables erythropoiesis in the absence of epor and jak2. Blood 2008, 111, 4511-4522.
27. Kerenyi, M.A.; Grebien, F.; Gehart, H.; Schifrer, M.; Artaker, M.; Kovacic, B.; Beug, H.; Moriggl, R.; Mullner, E.W. Stat5 regulates cellular iron uptake of erythroid cells via irp-2 and tfr-1. Blood 2008, 112, 3878-3888.
28. Lewis, R.S.; Ward, A.C. Stat5 as a diagnostic marker for leukemia. Expert Rev. Mol. Diagn. 2008, 8, 73-82.
29. Liu, S.; Walker, S.R.; Nelson, E.A.; Cerulli, R.; Xiang, M.; Toniolo, P.A.; Qi, J.; Stone, R.M.; Wadleigh, M.; Bradner, J.E.; et al. Targeting stat5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (bet) bromodomain protein brd2. Mol. Cancer Ther. 2014, 13, 1194-1205.
30. Sternberg, D.W.; Gilliland, D.G. The role of signal transducer and activator of transcription factors in leukemogenesis. J. Clin. Oncol. 2004, 22, 361-371.
31. Scheeren, F.A.; Diehl, S.A.; Smit, L.A.; Beaumont, T.; Naspetti, M.; Bende, R.J.; Blom, B.; Karube, K.; Ohshima, K.; van Noesel, C.J.; et al. Il-21 is expressed in hodgkin lymphoma and activates stat5: Evidence that activated stat5 is required for hodgkin lymphomagenesis. Blood 2008, 111, 4706-4715.
32. Hoelbl, A.; Kovacic, B.; Kerenyi, M.A.; Simma, O.; Warsch, W.; Cui, Y.; Beug, H.; Hennighausen, L.; Moriggl, R.; Sexl, V. Clarifying the role of stat5 in lymphoid development and abelson-induced transformation. Blood 2006, 107, 4898-4906.
33. Walz, C.; Ahmed, W.; Lazarides, K.; Betancur, M.; Patel, N.; Hennighausen, L.; Zaleskas, V.M.; van Etten, R.A. Essential role for stat5a/b in myeloproliferative neoplasms induced by bcr-abl1 and jak2(v617f) in mice. Blood 2012, 119, 3550-3560.
34. Goldman, J.M.; Melo, J.V. Bcr-abl in chronic myelogenous leukemia-How does it work? Acta Haematol. 2008, 119, 212-217.
35. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; et al. Activating mutation in the tyrosine kinase jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387-397.
36. Funakoshi-Tago, M.; Tago, K.; Abe, M.; Sonoda, Y.; Kasahara, T. Stat5 activation is critical for the transformation mediated by myeloproliferative disorder-associated jak2 v617f mutant. J. Biol. Chem. 2010, 285, 5296-5307.
37. Hoelbl, A.; Schuster, C.; Kovacic, B.; Zhu, B.; Wickre, M.; Hoelzl, M.A.; Fajmann, S.; Grebien, F.; Warsch, W.; Stengl, G.; et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol. Med. 2010, 2, 98-110.
38. Vainchenker, W.; Constantinescu, S.N. Jak/stat signaling in hematological malignancies. Oncogene 2013, 32, 2601-2613.
39. Warsch, W.; Kollmann, K.; Eckelhart, E.; Fajmann, S.; Cerny-Reiterer, S.; Holbl, A.; Gleixner, K.V.; Dworzak, M.; Mayerhofer, M.; Hoermann, G.; et al. High stat5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011, 117, 3409-3420.
40. Hantschel, O.; Warsch, W.; Eckelhart, E.; Kaupe, I.; Grebien, F.; Wagner, K.U.; Superti-Furga, G.; Sexl, V. Bcr-abl uncouples canonical jak2-stat5 signaling in chronic myeloid leukemia. Nature Chem. Biol. 2012, 8, 285-293.
41. Bar-Natan, M.; Nelson, E.A.; Walker, S.R.; Kuang, Y.; Distel, R.J.; Frank, D.A. Dual inhibition of jak2 and stat5 enhances killing of myeloproliferative neoplasia cells. Leukemia 2012, 26, 1407-1410.
42. Nelson, E.A.; Walker, S.R.; Weisberg, E.; Bar-Natan, M.; Barrett, R.; Gashin, L.B.; Terrell, S.; Klitgaard, J.L.; Santo, L.; Addorio, M.R.; et al. The stat5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011, 117, 3421-3429.
43. Verdine, G.L.; Walensky, L.D. The challenge of drugging undruggable targets in cancer: Lessons learned from targeting bcl-2 family members. Clin. Cancer Res. 2007, 13, 7264-7270.
44. Weber, A.; Borghouts, C.; Brendel, C.; Moriggl, R.; Delis, N.; Brill, B.; Vafaizadeh, V.; Groner, B. The inhibition of stat5 by a peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells. Pharmaceuticals 2013, 6, 960-987.
45. Borghouts, C.; Kunz, C.; Delis, N.; Groner, B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol. Cancer Res. MCR 2008, 6, 267-281.
46. Heuser, M.; Sly, L.M.; Argiropoulos, B.; Kuchenbauer, F.; Lai, C.; Weng, A.; Leung, M.; Lin, G.; Brookes, C.; Fung, S.; et al. Modeling the functional heterogeneity of leukemia stem cells: Role of stat5 in leukemia stem cell self-renewal. Blood 2009, 114, 3983-3993.
47. Choudhary, C.; Brandts, C.; Schwable, J.; Tickenbrock, L.; Sargin, B.; Ueker, A.; Bohmer, F.D.; Berdel, W.E.; Muller-Tidow, C.; Serve, H. Activation mechanisms of stat5 by oncogenic flt3-itd. Blood 2007, 110, 370-374.
48. Harir, N.; Pecquet, C.; Kerenyi, M.; Sonneck, K.; Kovacic, B.; Nyga, R.; Brevet, M.; Dhennin, I.; Gouilleux-Gruart, V.; Beug, H.; et al. Constitutive activation of stat5 promotes its cytoplasmic localization and association with pi3-kinase in myeloid leukemias. Blood 2007, 109, 1678-1686.
49. George, R.E.; Sanda, T.; Hanna, M.; Frohling, S.; Luther, W., 2nd; Zhang, J.; Ahn, Y.; Zhou, W.; London, W.B.; McGrady, P.; et al. Activating mutations in alk provide a therapeutic target in neuroblastoma. Nature 2008, 455, 975-978.
50. Gesbert, F.; Griffin, J.D. Bcr/abl activates transcription of the bcl-x gene through stat5. Blood 2000, 96, 2269-2276.
51. Lacronique, V.; Boureux, A.; Monni, R.; Dumon, S.; Mauchauffe, M.; Mayeux, P.; Gouilleux, F.; Berger, R.; Gisselbrecht, S.; Ghysdael, J.; et al. Transforming properties of chimeric tel-jak proteins in ba/f3 cells. Blood 2000, 95, 2076-2083.
52. Mayerhofer, M.; Gleixner, K.V.; Hoelbl, A.; Florian, S.; Hoermann, G.; Aichberger, K.J.; Bilban, M.; Esterbauer, H.; Krauth, M.T.; Sperr, W.R.; et al. Unique effects of kit d816v in baf3 cells: Induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J. Immunol. 2008, 180, 5466-5476.
53. Onishi, M.; Nosaka, T.; Misawa, K.; Mui, A.L.; Gorman, D.; McMahon, M.; Miyajima, A.; Kitamura, T. Identification and characterization of a constitutively active stat5 mutant that promotes cell proliferation. Mol. Cell. Biol. 1998, 18, 3871-3879.
54. Baskiewicz-Masiuk, M.; Masiuk, M.; Machalinski, B. The influence of stat5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines. Cell Prolif. 2003, 36, 265-278.
55. Kosova, B.; Tezcanli, B.; Ekiz, H.A.; Cakir, Z.; Selvi, N.; Dalmizrak, A.; Kartal, M.; Gunduz, U.; Baran, Y. Suppression of stat5a increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive k562 cells. Leuk. Lymphoma 2010, 51, 1895-1901.
56. Wang, X.; Zeng, J.; Shi, M.; Zhao, S.; Bai, W.; Cao, W.; Tu, Z.; Huang, Z.; Feng, W. Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic k562 cell growth. DNA Cell Biol. 2011, 30, 71-78.
57. Chueh, F.Y.; Leong, K.F.; Yu, C.L. Mitochondrial translocation of signal transducer and activator of transcription 5 (stat5) in leukemic t cells and cytokine-stimulated cells. Biochem. Biophys. Res. Commun. 2010, 402, 778-783.
58. Lee, J.E.; Yang, Y.M.; Liang, F.X.; Gough, D.J.; Levy, D.E.; Sehgal, P.B. Nongenomic stat5-dependent effects on golgi apparatus and endoplasmic reticulum structure and function. Am. J. Physiol. Cell Physiol. 2012, 302, C804-C820.
59. Mohr, A.; Chatain, N.; Domoszlai, T.; Rinis, N.; Sommerauer, M.; Vogt, M.; Muller-Newen, G. Dynamics and non-canonical aspects of jak/stat signalling. Eur. J. Cell Biol. 2012, 91, 524-532.
60. Basham, B.; Sathe, M.; Grein, J.; McClanahan, T.; D’Andrea, A.; Lees, E.; Rascle, A. In vivo identification of novel stat5 target genes. Nucl. Acids Res. 2008, 36, 3802-3818.
61. De Groot, R.P.; Raaijmakers, J.A.; Lammers, J.W.; Koenderman, L. Stat5-dependent cyclind1 and bcl-xl expression in bcr-abl-transformed cells. Mol. Cell Biol. Res. Commun. MCBRC 2000, 3, 299-305.
62. Epling-Burnette, P.K.; Zhong, B.; Bai, F.; Jiang, K.; Bailey, R.D.; Garcia, R.; Jove, R.; Djeu, J.Y.; Loughran, T.P., Jr.; Wei, S. Cooperative regulation of mcl-1 by janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J. Immunol. 2001, 166, 7486-7495.
63. Matsumura, I.; Kitamura, T.; Wakao, H.; Tanaka, H.; Hashimoto, K.; Albanese, C.; Downward, J.; Pestell, R.G.; Kanakura, Y. Transcriptional regulation of the cyclin d1 promoter by stat5: Its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999, 18, 1367-1377.
64. Paukku, K.; Silvennoinen, O. Stats as critical mediators of signal transduction and transcription: Lessons learned from stat5. Cytokine Growth Factor Rev. 2004, 15, 435-455.
65. Irino, T.; Uemura, M.; Yamane, H.; Umemura, S.; Utsumi, T.; Kakazu, N.; Shirakawa, T.; Ito, M.; Suzuki, T.; Kinoshita, K. Jak2 v617f-dependent upregulation of pu.1 expression in the peripheral blood of myeloproliferative neoplasm patients. PLOS ONE 2011, 6, e22148.
66. Kawano, T.; Ito, M.; Raina, D.; Wu, Z.; Rosenblatt, J.; Avigan, D.; Stone, R.; Kufe, D. Muc1 oncoprotein regulates bcr-abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007, 67, 11576-11584.
67. Salas, E.M.; Garcia-Barchino, M.J.; Labiano, S.; Shugay, M.; Perez-Encinas, M.; Quinteiro, C.; Garcia-Delgado, M.; Vizmanos, J.L.; Novo, F.J. Lif, a novel stat5-regulated gene, is aberrantly expressed in myeloproliferative neoplasms. Genes Cancer 2011, 2, 593-596.
68. Tokunaga, M.; Ezoe, S.; Tanaka, H.; Satoh, Y.; Fukushima, K.; Matsui, K.; Shibata, M.; Tanimura, A.; Oritani, K.; Matsumura, I.; et al. Bcr-abl but not jak2 v617f inhibits erythropoiesis through the ras signal by inducing p21cip1/waf1. J. Biol. Chem. 2010, 285, 31774-31782.
69. Yao, Z.; Kanno, Y.; Kerenyi, M.; Stephens, G.; Durant, L.; Watford, W.T.; Laurence, A.; Robinson, G.W.; Shevach, E.M.; Moriggl, R.; et al. Nonredundant roles for stat5a/b in directly regulating foxp3. Blood 2007, 109, 4368-4375.
70. Schwemmers, S.; Will, B.; Waller, C.F.; Abdulkarim, K.; Johansson, P.; Andreasson, B.; Pahl, H.L. Jak2v617f-negative et patients do not display constitutively active jak/stat signaling. Exp. Hematol. 2007, 35, 1695-1703.
71. Von Manstein, V.; Yang, C.M.; Richter, D.; Delis, N.; Vafaizadeh, V.; Groner, B. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr. Signal Transduct. Ther. 2013, 8, 193-202.
72. Chatain, N.; Ziegler, P.; Fahrenkamp, D.; Jost, E.; Moriggl, R.; Schmitz-Van de Leur, H.; Muller-Newen, G. Src family kinases mediate cytoplasmic retention of activated stat5 in bcr-abl-positive cells. Oncogene 2013, 32, 3587-3597.
73. Kosan, C.; Ginter, T.; Heinzel, T.; Krämer, O.H. Stat5 acetylation - mechanisms and consequences for immunological control and leukemogenesis. JAK-STAT 2013, 3, e26102.
74. Li, G.; Miskimen, K.L.; Wang, Z.; Xie, X.Y.; Brenzovich, J.; Ryan, J.J.; Tse, W.; Moriggl, R.; Bunting, K.D. Stat5 requires the n-domain for suppression of mir15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood 2010, 115, 1416-1424.
75. Lockyer, H.M.; Tran, E.; Nelson, B.H. Stat5 is essential for akt/p70s6 kinase activity during il-2-induced lymphocyte proliferation. J. Immunol. 2007, 179, 5301-5308.
76. Wofford, J.A.; Wieman, H.L.; Jacobs, S.R.; Zhao, Y.; Rathmell, J.C. Il-7 promotes glut1 trafficking and glucose uptake via stat5-mediated activation of akt to support t-cell survival. Blood 2008, 111, 2101-2111.
77. Zhang, Y.; Diaz-Flores, E.; Li, G.; Wang, Z.; Kang, Z.; Haviernikova, E.; Rowe, S.; Qu, C.K.; Tse, W.; Shannon, K.M.; et al. Abnormal hematopoiesis in gab2 mutant mice. Blood 2007, 110, 116-124.
78. Wolf, A.; Eulenfeld, R.; Gäbler, K.; Rolvering, C.; Haan, S.; Behrmann, I.; Denecke, B.; Haan, C.; Schaper, F. Jak2-v617f-induced mapk activity is regulated by pi3k and acts synergistically with pi3k on the proliferation of jak2-v617f-positive cells. JAK-STAT 2013, 2, PMID: 24069558.
79. Borghouts, C.; Delis, N.; Brill, B.; Weiss, A.; Mack, L.; Lucks, P.; Groner, B. A membrane penetrating aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. JAK-STAT 2012, 1, 44-54.
80. Nam, S.; Williams, A.; Vultur, A.; List, A.; Bhalla, K.; Smith, D.; Lee, F.Y.; Jove, R. Dasatinib (bms-354825) inhibits STAT5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 2007, 6, 1400-1405.
81. Yang, S.H.; Chien, C.M.; Su, J.C.; Chen, Y.L.; Chang, L.S.; Lin, S.R. Novel indoloquinoline derivative, iqdma, inhibits stat5 signaling associated with apoptosis in k562 cells. J. Biochem. Mol. Toxicol. 2008, 22, 396-404.
82. Quentmeier, H.; MacLeod, R.A.; Zaborski, M.; Drexler, H.G. Jak2 v617f tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006, 20, 471-476.
83. Demaison, C.; Parsley, K.; Brouns, G.; Scherr, M.; Battmer, K.; Kinnon, C.; Grez, M.; Thrasher, A.J. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 2002, 13, 803-813.
84. Koptyra, M.; Gupta, S.; Talati, P.; Nevalainen, M.T. Signal transducer and activator of transcription 5a/b: Biomarker and therapeutic target in prostate and breast cancer. Int. J. Biochem. Cell Biol. 2011, 43, 1417-1421.
85. Warsch, W.; Walz, C.; Sexl, V. Jak of all trades: Jak2-stat5 as novel therapeutic targets in bcr-abl1+ chronic myeloid leukemia. Blood 2013, 122, 2167-2175.
86. Xiang, M.; Birkbak, N.J.; Vafaizadeh, V.; Walker, S.R.; Yeh, J.E.; Liu, S.; Kroll, Y.; Boldin, M.; Taganov, K.; Groner, B.; et al. Stat3 induction of mir-146b forms a feedback loop to inhibit the nf-kappab to il-6 signaling axis and stat3-driven cancer phenotypes. Sci. Signal. 2014, 7, ra11.
87. Walker, S.R.; Xiang, M.; Frank, D.A. Stat3 activity and function in cancer: Modulation by stat5 and mir-146b. Cancers 2014, 6, 958-968.
88. Frank, D.A. Stat3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007, 251, 199-210.
89. Dagvadorj, A.; Kirken, R.A.; Leiby, B.; Karras, J.; Nevalainen, M.T. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin. Cancer Res. 2008, 14, 1317-1324.
90. Li, G.; Miskimen, K.L.; Wang, Z.; Xie, X.Y.; Tse, W.; Gouilleux, F.; Moriggl, R.; Bunting, K.D. Effective targeting of stat5-mediated survival in myeloproliferative neoplasms using abt-737 combined with rapamycin. Leukemia 2010, 24, 1397-1405.
91. Dagvadorj, A.; Tan, S.H.; Liao, Z.; Xie, J.; Nurmi, M.; Alanen, K.; Rui, H.; Mirtti, T.; Nevalainen, M.T. N-terminal truncation of stat5a/b circumvents pias3-mediated transcriptional inhibition of stat5 in prostate cancer cells. Int. J. Biochem. Cell Biol. 2010, 42, 2037-2046.
92. Berger, A.; Hoelbl-Kovacic, A.; Bourgeais, J.; Hoefling, L.; Warsch, W.; Grundschober, E.; Uras, I.Z.; Menzl, I.; Putz, E.M.; Hoermann, G.; et al. Pak-dependent stat5 serine phosphorylation is required for bcr-abl-induced leukemogenesis. Leukemia 2014, 28, 629-641.
93. Friedbichler, K.; Kerenyi, M.A.; Kovacic, B.; Li, G.; Hoelbl, A.; Yahiaoui, S.; Sexl, V.; Mullner, E.W.; Fajmann, S.; Cerny-Reiterer, S.; et al. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 2010, 116, 1548-1558.
94. Shin, H.Y.; Reich, N.C. Dynamic trafficking of stat5 depends on an unconventional nuclear localization signal. J. Cell Sci. 2013, 126, 3333-3343.
95. Han, J.; Yu, C.; Souza, R.F.; Theiss, A.L. Prohibitin 1 modulates mitochondrial function of stat3. Cell. Signal. 2014, 26, 2086-2095.
96. Khan, R.; Lee, J.E.; Yang, Y.M.; Liang, F.X.; Sehgal, P.B. Live-cell imaging of the association of stat6-gfp with mitochondria. PLOS ONE 2013, 8, e55426.
97. Hu, X.; Dutta, P.; Tsurumi, A.; Li, J.; Wang, J.; Land, H.; Li, W.X. Unphosphorylated stat5a stabilizes heterochromatin and suppresses tumor growth. Proc. Natl. Acad. Sci. USA 2013, 110, 10213-10218.
98. Gu, L.; Liao, Z.; Hoang, D.T.; Dagvadorj, A.; Gupta, S.; Blackmon, S.; Ellsworth, E.; Talati, P.; Leiby, B.; Zinda, M.; et al. Pharmacologic inhibition of jak2-stat5 signaling by jak2 inhibitor azd1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin. Cancer Res. 2013, 19, 5658-5674.
99. Cumaraswamy, A.A.; Lewis, A.M.; Geletu, M.; Todic, A.; Diaz, D.B.; Cheng, X.R.; Brown, C.E.; Laister, R.C.; Muench, D.; Kerman, K.; et al. Nanomolar-potency small molecule inhibitor of stat5 protein. ACS Med. Chem. Lett. 2014, 5, 1202-1206.
100. Corbin, A.S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M.W.; Druker, B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of bcr-abl activity. J. Clin. Investig. 2011, 121, 396-409.
101. Hamilton, A.; Helgason, G.V.; Schemionek, M.; Zhang, B.; Myssina, S.; Allan, E.K.; Nicolini, F.E.; Muller-Tidow, C.; Bhatia, R.; Brunton, V.G.; et al. Chronic myeloid leukemia stem cells are not dependent on bcr-abl kinase activity for their survival. Blood 2012, 119, 1501-1510.
102. Groner, B.; Weber, A.; Mack, L. Increasing the range of drug targets: Interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered 2012, 3, 320-325.